(Q24245058)

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Single or multiple daily doses of aminoglycosides: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Trials to assess equivalence: the importance of rigorous methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

Single versus combination intravenous antibiotic therapy for people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

[Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Survey of acute renal failure in patients with cystic fibrosis in the UK.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Case-control study of acute renal failure in patients with cystic fibrosis in the UK.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

1 reference

7 January 2021

Intravenous antibiotics at home in children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002009.PUB2

7 January 2021